Jacobus Worldwide Recall of Ruzurgi® (amifampridine) 10 mg Tablets Due to Mold, Yeast, and Bacterial Contamination According to the FDA and Jacobus Pharmaceutical Company Incorporated, three lots of Ruzurgi® (amifampridine) 10 mg tablets have been recalled due to mold, yeast, and aerobic bacteria contamination. The recall applies to the consumer/patient level. Medications that are heavily contaminated with […]
According to the FDA and Jacobus Pharmaceutical Company Incorporated, three lots of Ruzurgi® (amifampridine) 10 mg tablets have been recalled due to mold, yeast, and aerobic bacteria contamination. The recall applies to the consumer/patient level.
Medications that are heavily contaminated with mold, aerobic bacteria, or yeast can cause “serious and life-threatening infections.” A patient with underlying immunosuppressive medical conditions such as Lambert Eaton Syndrome (LEMS) raises the risk of serious infection.
Ruzurgi® (amifampridine) 10 mg tablets are used to treat patients ages 6 to 17 with LEMS. The packaged in 100 count bottles (NDC: 49938-110-01). The affected Ruzurgi® (amifampridine) tablets lots are packaged in 100-count bottles, have an NDC of 49938-110-01, and include one of the following expiration dates and control numbers:
The Control Number can be found below the D2 Barcode and at the right of the bottle’s front panel.
Ruzurgi® (amifampridine) is distributed worldwide to specialty physicians and pharmacies. Consumers that have one of the affected Ruzurgi® (amifampridine) products should immediately stop using the product and return the product for a replacement.
Were you or a loved one harmed due to Ruzurgi? Parker Waichman LLP helps families recover monetary compensation for their injuries caused by defective products. For your free consultation, contact our law firm today by using our live chat or calling 1-800-YOUR-LAWYER (1-800-968-7529).